- DarioHealth Corp. reported its second quarter financial results Aug. 12, showing a revenue increase on a quarter-to-quarter basis, as well as gross profit increases of 95 percent and 60 percent on year-over-year quarterly and six-month measures, respectively
- CEO Erez Raphael recently appeared on Fox Business news forum “The Claman Countdown” to discuss the company’s health and the state of the telemedicine industry amid reports of high-value M&A activity
- Telemedicine has gained significant popularity as a means of maintaining health standards while reducing or eliminating the risk of virus transmission during the ongoing COVID-19 pandemic
- U.S. President Donald Trump recently signed measures designed to make emergency authorization for insurance reimbursements for telehealth services more permanent beyond the duration of the pandemic, and many private insurers are beginning to follow suit
- DarioHealth has gained market attention as it has racked up successes in advancing its remote health monitoring platform for diabetes and hypertension patients where it is commercially available in the United States, Canada, the United Kingdom, Europe and Australia after clearing regulatory hurdles
- The company announced its first two remote patient monitoring agreements in North America in June, followed by an agreement covering the United Kingdom and Ireland in July
The innovative energy driving the health technology company DarioHealth (NASDAQ: DRIO) has generated a series of successes for the small-cap company, and DarioHealth is anticipating additional developments in the coming weeks that may help the company continue to grow and mature, according to CEO Erez Raphael in the company’s just-released Q2 financial statement.
“The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (B2B2C) digital therapeutics leader,” Raphael stated in the Aug. 12 statement…
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.